SAN DIEGO—(BUSINESS WIRE)—Aug. 23, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system disorders,today announced that the underwriters for the Company’s previouslyannounced public offering have fully exercised their option to purchasean additional 909,090 shares. All 6,969,696 shares sold in the offeringwere offered by ACADIA at a price to the public of $33.00 per share, fortotal gross proceeds to ACADIA of approximately $230.0 million beforededucting underwriting discounts and commissions and other offeringexpenses payable by ACADIA. The closing of the sale of 6,060,606 shareswas completed on August 15, 2016, and the closing of the sale of 909,090shares pursuant to the full exercise by the underwriters of their optionto purchase additional shares was completed earlier today.
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynchacted as the joint book-running managers for the offering. Cowen andCompany, LLC, Piper Jaffray & Co. and Needham & Company, LLC acted asco-managers for the offering.
The shares of common stock described above were offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective on March 3, 2014. A final prospectus supplement andaccompanying prospectus relating to the offering have been filed withthe SEC and are available on the SEC’s website located at http://www.sec.gov.Copies of the final prospectus supplement and the accompanyingprospectus related to this offering may be obtained from J.P. MorganSecurities LLC, c/o Broadridge Financial Solutions, 1155 Long IslandAvenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or byemail to: prospectus-eq_fi@jpmchase.com,or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 WestStreet, New York, NY 10282, or by telephone at (866) 471-2526, or byemail to: prospectus-ny@ny.email.gs.com,or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rdfloor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or byemail to: dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, SeniorDirector, Investor Relations
(858) 558-2871